Bermejo-Pareja F, Puertas-MartÃn V Cognitive Features of Essential Tremor: A Review of the Clinical Aspects and Possible Mechanistic Underpinnings. Tremor and Other Hyperkinetic Movements [Internet]. 2012 Sep 14 [cited 2021 Oct 9];2(0). Available from: http://tremorjournal.org/articles/10.5334/tohm.106/
Louis ED, Joyce JL, Cosentino S Mind the gaps: What we don't know about cognitive impairment in essential tremor. Parkinsonism Relat Disord [Internet]. 2019 Jun 1 [cited 2021 Oct 9];63:10-9. Available from: http://www.prd-journal.com/article/S1353802019300860/fulltext
Rahman TT, El Gaafary MM Montreal Cognitive Assessment Arabic version: reliability and validity prevalence of mild cognitive impairment among elderly attending geriatric clubs in Cairo. Geriatr Gerontol Int. 2009 Mar;9(1):54-61. doi: 10.1111/j.1447-0594.2008.00509.x.
Rao AK, Louis ED Ataxic Gait in Essential Tremor: A Disease-Associated Feature? Tremor and Other Hyperkinetic Movements [Internet]. 2019 Jun 19 [cited 2021 Oct 9];9(0). Available from: http://tremorjournal.org/articles/10.5334/tohm.507/
Wechsler memory scale - PsycNET [Internet]. [cited 2021 Oct 25]. Available from: https://psycnet.apa.org/record/1946-00348-000
Williams JB A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988 Aug;45(8):742-7.
Yilmaz NH, Akbostanci MC, Yilmaz N Sensorineural Hearing Loss in Non-depressed Essential Tremor Cases and Controls: A Clinical and Audiometric Study. Tremor and Other Hyperkinetic Movements [Internet]. 2015 Jan 29 [cited 2021 Oct 9];5(0):281. Available from: http://tremorjournal.org/articles/10.5334/tohm.237
Clinical Profile in Patients With Essential Tremors
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
